[ad_1]
Johnson & Johnson is resuming manufacturing of its Covid-19 vaccine at the factory of a contract manufacturer that makes the main ingredient, after a production issue ruined a batch.
In order to give J&J full control, production of AstraZeneca PLC’s vaccine at the Emergent BioSolutions Inc. plant in Baltimore will move elsewhere, according to a person familiar with the matter.
The moves, which the person said were facilitated by the Biden administration and confirmed by companies, mark a swift response to the recent discovery of the contaminated lot. The New York Times first reported that J&J had taken control of the plant.
The Emergent plant had not yet been cleared by regulators when J&J discovered the quality problem during a routine inspection, and no lots had been shipped for use in making vaccines.
Still, J&J and U.S. health officials are eagerly awaiting the plant’s launch and production of the key ingredient to bolster the overall supply of vaccine doses.
Source link
